

NOVEL HYBRID ANTIBIOTICS

Fáze vývoje technologie

Fáze 2

Výzkum proveditelnosti.

Dochází k reálnému návrhu technologie a k prvotním testům v laboratoři vedoucím k upřesnění požadavků na technologii a jejích schopností.

Status IP ochrany

Protected by WO2018161979 (A1) (EU and US); CZ307305 (B6), granted 11.04.2018; priority 10.03.2017

Strategie pro hledání partnera

Investice, Co-development, Licencování, Spolupráce

Warning: file_put_contents(): Only 0 of 193 bytes written, possibly out of free disk space in **/home/transfera.cz/htdocs/portfolio/lib/coreerrors.class.php** on line **216**

Instituce



Mikrobiologický ústav AV ČR, v. v. i.

Motivace

Finding solutions to rising resistance to existing antibiotics becomes of high importance nowadays. There is a constant call for a new-in-class or advanced-in-class antibiotics with the potential to improve this global situation. We developed and partially tested two new hybrid lincosamide compounds, which could have such potential.

Popis

Lincosamides are ribosome targeting antibiotics of high clinical relevance. Natural compound lincomycin is recently used mainly in veterinary medicine while its chlorinated derivative clindamycin, is listed by WHO as one of the key access antibiotics, the essential medicines, which should be available, affordable and quality-assured worldwide. Typically, it is used against infections caused by G+ staphylococci and streptococci, including methicillin-resistant *Staphylococcus aureus* (MRSA), one of four most relevant clinical indications, owing to the prevalence and severity of these conditions globally. However, increasing incidence of MRSA strains with associated macrolide-lincosamide-streptogramin (MLS) cross-resistance becomes a limiting factor to use clindamycin against MRSA. Due to the excellent tissue (including bone) penetration of clindamycin, it is the first choice drug to treat bone and teeth infections and also deep abdominal infections and some anaerobic infections (G+ or G-). However, inefficacy of lincosamides (as well as many other antibiotics) could result in pseudomembranous colitis, the serious risk factor of antibiotic treatment. In combination with quinine or quinolones, clindamycin is also used to treat malaria. Due to low toxicity, the combination quinine/clindamycin is recommended by WHO as the first choice drug for pregnant women and compromised patients in general. Among other parasites also *Toxoplasma* and *Babesia* could be treated by clindamycin. We developed and partially tested two new hybrid lincosamide compounds: The first one, ODCELIN is a hybrid molecule of two natural lincosamides, lincomycin and celesticetin and thus can be produced directly by modified microorganism, the second one Cl-ODCELIN is its chlorinated derivative. Preliminary tests indicated, that the both new compounds aspire to be superior drugs, if compared to their industrially used analogs: ODCELIN over lincomycin and Cl-ODCELIN over clindamycin. Most importantly, however, they

v. i.

represent a patented scaffold ready for further improvement and trigger to be investment attractive agents. Advantages over existing solutions

- In terms of MIC for *S. aureus* including MRSA, *Staphylococcus epidermidis*, *S. haemolyticus* or enterococci, ODCELIN is superior to lincomycin and CI-ODCELIN is superior to clindamycin.
- >10x improved activity even for strains with *ermC* (MLS) resistance determinant.
- 7 of 8 tested clindamycin resistant strains of *Clostridium difficile* are sensitive to CI-ODCELIN (prevailing MICs even below 0.25 µg/ml).
- The chemical and/or biological synthesis of the ODCELIN and CI-ODCELIN available.
- The engineered microorganism producer of the core compound is currently under construction.
- The engineered microorganism producer of the core compound is currently under construction.

Komerční využití

Co-development / collaboration: We offer the opportunity to exploit the patented lincosamide scaffold for further development to obtain the antibiotic able to overcome resistance caused by methylation of a ribosomal target. Investment /licensing: 1) We offer relatively cheap way how to gain more efficient compounds ODCELIN and CI-ODCELIN when compared to currently available lincomycin and clindamycin, respectively. ODCELIN could be produced in the same cost-efficient manner as lincomycin, i.e. from the fermentation broth of genetically engineered producing microorganism and CI-ODCELIN by its chlorination. Alternatively, they can be synthesized chemically from generic compound lincomycin. 2) A chance to develop the antibiotic overcoming resistance mechanisms: It represents a platform for further improvement at the patented hotspot as well as at two other already published hotspots of the molecule. Just the combination of patented modification with some already known seems to be promising to overcome resistance caused by methylation of ribosomal target. The product could reach the market size in human medicine ~150 mil. USD/year just in USA (600 mil. USD/year in total considering that USA covers 25% of the world market). At least the same size of market is further represented by veterinary medicine. (Estimated based on current market size for clindamycin and lincomycin)